I learned from Beijing Yimiao Shenzhou Biomedical Co., Ltd., that the company's first self-developed CAR-T cell drug, Poggiolensis injection, obtained a “Drug Registration Certificate” issued by the State Drug Administration to treat patients with recurrent or refractory large B-cell lymphoma in adults after second-line or above systematic treatment. This is also the first CAR-T cell drug approved in Beijing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.